CD38, a multifunctional ectoenzyme highly expressed on plasma cells but also on other lymphoid and myeloid cell populations, may be pharmacologically attractive for targeting plasma cells in SSc patients, as demonstrated by the beneficial effect obtained by two anti-CD38 monoclonal antibodies, daratumumab and isatuximab, in patients with multiple myeloma. Here, CD38 is linked to systemic sclerosis.